Interview : Frank Sloan by Charles Gerena
RF: Much of your research has focused on factors that
influence the cost, quality, and utilization of health care.
Do you think this market is fundamentally different
from other markets?
Sloan: There are things that set it apart, but some people
go off the deep end and say there’s nothing we can learn
from other markets. One thing that health care and other
markets have in common is that people respond to incen-
tives. Another thing is that competition may produce some
desirable outcomes. Markets won’t take care of poor people,
but they are a way to achieve efficiencies.
What is different about health care is the uncertainty of
consumption. You don’t know today that you might have 
surgery in two months, so that leads to demand for insurance.
Insurance stands between the people who provide
health care services and those who use them, but it’s possi-
ble to oversimplify that relationship. Compulsory auto
insurance is a way that we are able to tax those people who
drink a lot and drive under the influence. The difference is
that we find it socially OK— in fact, preferable — to expe-
rience-rate auto drivers in some states. We wouldn’t do that
in health care.
Another difference in the health care market is the exter-
nalities. People are afraid that if somebody coughs they will
get the flu. Those are public health externalities. Another
kind is financial externalities. If somebody gets lung cancer
and needs a lung transplant, that is typically done at public
expense. If people are disabled because of their smoking,
they get Social Security disability insurance and that is shared
by everyone. Then we have the “bleeding heart” externality.
The fact that I care that a poor person has adequate con-
sumption is something that will not be solved by markets. 
Also on the list of differences is the “public good” aspect
of biomedical research. Much of the improvement in health
is due to this research, yet a private market will never pro-
vide all of it. We have relied on patents to provide an incen-
tive, but they are imperfect solutions. They grant monopoly
power to a seller, so the quantity supplied is lower and the
price is higher than it would otherwise be.
RF: It seems as if there is a similar problem with 
providing incentives for vaccine production.
Sloan: Vaccines are a case in point. The general impres-
sion that many experts have, which I think is correct, is
that vaccines are undervalued. Some of the greatest health 
benefits have come from vaccines. During my lifetime, we
no longer talk about getting polio, so we don’t have to
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Type “health care” into a Google search and 
you’ll get more than 24 million web pages 
devoted to the subject. That’s not surprising
given the personal stake that Americans have 
in how the economy supplies this vital service. 
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with economic factors, shape the decisions of
people who provide and purchase health care.
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work at Duke University.
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analyses of the cost-effectiveness of medical 
technologies, and medical malpractice. Charles
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because we can actually prevent the disease.
RF: Some people have suggested that the government
get more involved in the vaccine market as a purchaser.
Sloan: The government already is very involved in being 
a buyer of childhood vaccines. The problem is that it has
such market power that the vaccine price is too low and not
enough of an incentive to entice new suppliers. As govern-
ment agencies get lower and lower prices for vaccines, 
manufacturers want to leave the business. 
The question is how to structure incentives for entry.
One suggestion is to pay vaccine manufacturers the social
value of their products. That sounds like a good idea, but
you are essentially giving economic rents to the manufac-
turers. This would be socially objectionable on distribu-
tional grounds. Another way to do it is for the government
to  have in its head what the value of a vaccine is, then 
negotiate with the manufacturers to get the best price that
it can, recognizing that the price will need to increase in 
order to get sufficient supply.
RF: Another hotly debated topic in health care lately is
whether to allow the reimportation of prescription
drugs. What are your views on that issue?
Sloan: The United States is a major importer of many goods.
In fact, in trying to resolve the recent flu vaccine shortage, the
federal government was willing to
work with other countries to import
vaccine. The policy concern about
importing drugs is mainly motivated
by attempts to satisfy the interests of
pharmaceutical manufacturers.
Having said this, drug importa-
tion is not a solution to the rising
cost of prescription drugs. Lower prices abroad reflect the
regulatory policies in other countries. If we want to import
drugs subject to price caps in other countries, it would be
more efficient to impose caps in this country.
According to the concept of comparative advantage, the
United States should produce goods and services for which
it has an advantage and import goods and services for which
it is at a disadvantage. Importing drugs manufactured in our
country does not represent comparative advantage.
RF: There has been a lot of discussion about the price of
medical care in general. Costs have outpaced overall
inflation by a large margin for some time. Why do you
think they are so high?
Sloan: First of all, I’m not sure that’s the right measure. Yes,
costs have been increasing. But can we say that the bene-
fits of improved health are worth it? The health of the pop-
ulation is clearly improving. Mortality is substantially
reduced. There is some evidence that, at least, the elderly
are less disabled than they used to be. They are living longer
but not living worse. It’s clear that if you did a report 
card on the benefits of improved
health for the elderly — we’ve done it
for four diseases — the benefits have
grown more than the costs.That is,
Medicare spending has grown less
than the value of the benefits.
RF: For a while, we tried to
reduce medical costs using managed care and health
maintenance organizations (HMOs). Now there is a
backlash against that approach and people want more
choices. What is your opinion?
Sloan: The concept is a good one: to provide incentives to
keep people healthy. If we can take care of people while they
are healthy, then maybe we will spend less when they are sick.
Also, given that we have so much insurance, individuals and
their doctors have an incentive to use service down to the
point where the marginal benefit is zero, and that is way too
much care. So theoretically, managed care is a great idea. In
practice, it is not such a good idea.
First of all, what incentive does my health plan provider
have to prevent illness in the future, when in fact I may not
even be around? Some people change jobs, some people get
married and drop coverage because their spouse has better
coverage, etc. When the health benefit is way downstream,
the impetus to control diabetes, to control weight, or to








































managed care is a great idea. 
In  practice, it is not so good.” 
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A second problem is that we were never able to get 
clinical findings in line with health plans. If we know that
doing certain things for people with diabetes improves their
health, we never implemented real incentives on a wide-
spread basis to give patients and their doctors a reason to do
those things. And protocols weren’t refined enough. They
were just blunt policies like, “You’ve got to see a general prac-
titioner before you can go to a specialist.” But the cardiolo-
gist may know more about preventing heart disease. The
endocrinologist may know more about diabetes. So now,
gatekeeping has been gutted.
At hird problem is that managed care never got the 
doctors on their side. Some nurse at the other end was
telling them how to practice medicine. So the doctors were
able to say the quality of care was going down the tubes and
they brought the issue into the legislative arena. Nearly
every state in the country enacted some patient protection
law. This had a chilling effect on the managed care industry.
The industry preemptively loosened up.
RF: Is there a good way to refine the managed care
approach, or should we go back to the drawing board?
Sloan: I think we need to reinvent it. We need to use evi-
dence-based protocols. Often, these protocols are based on
doctors getting together and saying, “I think having an annual
physical is a good thing.” We need evidence. 
Evidence does not always lead you to spend less, 
however. That’s what we had thought before with HMOs.
But the big dilemma for the future is that the evidence may
sometimes tell you to do the opposite. As our colonoscopies
get better, we may do more of them. As we refine diagnostic
imaging, we may do more. 
RF: Many lawmakers have blamed rising health care
costs on “frivolous lawsuits” for medical malpractice and
“defensive medicine” to stave off those lawsuits. Based
on your work and other economists’ research, how much
has this really contributed to cost increases?
Sloan: It has to be very small. First of all, premiums are 1
to 3 percent of health care expenditures. If you took all the
costs of inputs to hospitals and physicians’ practices, much
more is spent on other parts. Labor is much more, yet 
we don’t say we have a crisis in physician labor.
On the defensive medicine front, we have never 
developed an operational definition of what we mean by
that. Presumably, defensive medicine would be care that
yields a marginal benefit substantially lower than the cost.
If  we  look at Prostate-Specific Antigen testing for
prostate cancer, for example, you could say every time we 
get a negative finding that test was a waste, but, obviously, 
it was not. Then the question is which follow-up biopsy 
does the benefit exceed cost and which does not. Well, this
would require an in-depth study. It also depends on the risk
preferences of the person who is being tested. Some people
may have a need to know whether there is something grow-
ing inside them and would be willing, even in the absence of
insurance, to pay. 
We  need to determine whether, in the absence of the 
distortions in the market, this person would have been will-
ing to pay for this added diagnostic testing. It’s clear that
some people would, so we can’t say that all biopsies are a
waste. And if we said they were all a waste, we would elimi-
nate them and throw the doctors out of business. 
RF: You also have researched how the tort system, as well
as government regulation and market forces, influences
alcohol use. What have you found to be the best
deterrents for driving under the influence?
Sloan:  Incentives matter and disincentives 
matter. One of our interests has been how the
insurance system affects accident rates. If you have
a DUI offense on your record in this state, your
premium goes up remarkably and that is quite a
deterrent.
With “dram shop liability,” the server is held
liable if a patron leaves the bar under the influence
of alcohol and the server did not take precautions
to prevent that person from leaving, and that was
the cause of an accident that led to a fatality or
life-disabling injury. We found some evidence to
suggest that dram shop liability is a deterrent.
People at home just conk out and go to sleep. But
with people that have to go from point Ato point
B, the bartender is relatively efficient at prevent-
ing that accident. He might take the keys away. He
might refuse service. After some point, he may
water down the drinks. 
44 Region Focus • Winter 2005
RF Winter 04 FINAL.ps - 1/10/2005 13:56 PMRF: There are some people who
continue to drink too much or
smoke cigarettes despite the
deterrents and health risks. Do
they understand the risks? Is there
any difference in how smokers and
drinkers process information?
Sloan: We  should separate drinking
and smoking. Some moderate drink-
ing is presumably good for your
health. It’s drinking to excess that is a
problem. We have these various
externalities with somebody going
out on the highway drunk and driving
off the road. A lot of accidents
involve a single car, but some of them
don’t. Smoking is different because it
is clearly bad for your health and
most of the damage is to the self and
the immediate family. The external
effects are very small. 
Our most recent research has
found that smokers seem to process
information differently, in that cer-
tain health events were less impor-
tant in their own predictions of how
long they would live. But we are now
looking at this in much greater detail.
Are smokers more likely to be risk-
takers? Are they less future oriented?
Do they place less value on good
health? We are finding that they are
less future oriented and less risk
averse than nonsmokers.
Another way that smokers differ is they seem to be more
pessimistic about the future. If you ask them, “What is the
probability that we will have double-digit inflation?” or “What
is the probability that we will have another depression like in
the 1930s?” they are more likely to fear these adverse conse-
quences. These events don’t relate to the individual’s smoking
behavior, but may indicate that they feel more at the mercy of
external events, that they have less control over their lives.
RF: The United States is one of the few industrialized
countries without a comprehensive national health care
system. Without considering the merits of such a system,
why do you think we remain unique in this respect?
Sloan: To understand why we do not have national health insur-
ance as others do, one needs to investigate the historical context
under which this system was adopted in other countries. For
example, Germany adopted national health insurance over a
century ago as part of Bismarck’s industrialization policy. At
the time, health care costs were much lower than they are
presently and political opposition was weak. In England,
national health insurance was adopted
at an opportune time in the immedi-
ate post-World War II period. 
Once implemented, it is political-
ly impossible to take national health
insurance away, like Social Security in
the United States. To implement the
program, one must overcome sub-
stantial political opposition from
well-organized stakeholders. This
has been difficult to do in this coun-
try. Perhaps it could have been done
during the Johnson Administration
when Medicare and Medicaid were
implemented and the Democrats
had won the White House by a wide
margin and controlled both houses
of Congress.
RF: Are there particular econo-
mists who have influenced your
own work?
Sloan: I would say that it is a type of
economist. When I was in graduate
school, the best economists were
incredibly broad. They would know
foreign languages. They would know
history. Milton Friedman, Kenneth
Arrow, Paul Samuelson are a few
economists that exemplify this ideal,
as well as Wassily Leontief, who did
input-output analysis.
Then I was influenced by
younger economists. My main graduate school advisor was
Martin Feldstein. He was only three years older than me but
very engaged in policy. I would go in with my dissertation
and, in 15 minutes, he would run through it all so thoroughly 
that I would spend the rest of the day digesting what I had
learned.
Some people have criticized Marty on grounds that his
models are not sufficiently deep or complicated. But he is
very practical, and he relies on empirical evidence, not just on
abstract theorizing. Also, Marty has devoted part of his
career to public service. He has that broad kind of knowledge
and understands political constraints. He isn’t going to say
that government is stupid and should stay out of the way. He
has a lot of common sense.
I remember a professor who studied real-business
cycles and gave a seminar, one of the last macro seminars
I had attended. Somebody asked, “How does your model
fit the recession of 1974?” He said, “I don’t really study
those things.” That to me is unacceptable as an econo-
mist. I just don’t know what he’s accomplishing if he can’t
understand real-life phenomena and how to bring his
tools to bear on what’s going on. RF
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